Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies
CA Roldan,
BK Shively,
CC Lau,
FT Gurule,
EA Smith,
and
MH Crawford
Department of Veterans Affairs Medical Center, Albuquerque, New Mexico 87108.
OBJECTIVES. The aims of this study were to better characterize valve disease in systemic lupus erythematosus and to determine its association with antiphospholipid antibodies. BACKGROUND. Estimates of the prevalence of valve disease in systemic lupus erythematosus have been higher in autopsy series than in clinical studies using transthoracic echocardiography. Antiphospholipid antibodies have been suggested to be a primary pathogenetic factor. METHODS. Transesophageal echocardiography was performed on 1) 54 patients with lupus erythematosus, 22 of them with (group I) and 32 without (group II) antiphospholipid antibody; 2) on 10 patients with antiphospholipid syndrome (group III); and 3) on 35 normal subjects (group IV). RESULTS. Patients in groups I and III had similar types and concentrations of antibodies. Leaflet thickening was found in 50% of group I, 47% of group II, 10% of group III and 9% of group IV patients (group I or II vs. group III or IV, p < 0.03). Leaflet thickening in patients with lupus erythematosus was diffuse; it usually involved the mitral and aortic valves and was associated with valve regurgitation (73%) or valve masses (50%). Valve masses were observed in 41% of group I, 25% of group II, 10% of group III and in none of group IV patients (group I or II vs. group IV, p < 0.002). Most valve masses in patients with lupus erythematosus were located near the base on the atrial side of the mitral valve or on the vessel side of the aortic valve, had variable size (0.2 to 0.85 cm2), shape and echodensity. Valve regurgitation was observed in 64% of group I, 59% of group II, 10% of group III and 20% of group IV patients (group I or II vs. group III or IV, p < 0.006). Moderate or severe regurgitant lesions were noted in 27% of group I and 25% of group II patients. CONCLUSIONS. Lupus erythematosus valve disease is frequent (74%) regardless of the presence or absence of antiphospholipid antibodies. Therefore antiphospholipid antibodies may not be a primary pathogenetic factor. The characteristic appearance of leaflet thickening and masses in patients with lupus erythematosus may be unique.
This article has been cited by other articles:

|
 |

|
 |
 
J. Bourre-Tessier, T. Huynh, A. Clarke, S. Bernatsky, L. Joseph, P. Belisle, and C. Pineau
Features associated with cardiac abnormalities in systemic lupus erythematosus
Lupus,
December 1, 2011;
20(14):
1518 - 1525.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Zuily, V. Regnault, C. Selton-Suty, V. Eschwege, J.- F. Bruntz, E. Bode-Dotto, E. De Maistre, P. Dotto, C. Perret-Guillaume, T. Lecompte, et al.
Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: Meta-Analysis of Echocardiographic Studies
Circulation,
July 12, 2011;
124(2):
215 - 224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Cervera, M. Tektonidou, G. Espinosa, A. Cabral, E. Gonzalez, D. Erkan, S. Vadya, H. Adrogue, M. Solomon, G. Zandman-Goddard, et al.
Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions
Lupus,
February 1, 2011;
20(2):
165 - 173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Pardos-Gea, J. Ordi-Ros, G. Avegliano, J. Cortes-Hernandez, E. Balada, A. Evangelista, and M. Vilardell
Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients
Lupus,
April 1, 2010;
19(5):
575 - 582.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Lockhart, B. Loven, M. T. Brennan, and P. C. Fox
The evidence base for the efficacy of antibiotic prophylaxis in dental practice
J Am Dent Assoc,
April 1, 2007;
138(4):
458 - 474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z Szekanecz and Y Shoenfeld
Lupus and cardiovascular disease: the facts
Lupus,
November 1, 2006;
15(11_suppl):
3 - 10.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
F Tenedios, D Erkan, and M D Lockshin
Cardiac involvement in the antiphospholipid syndrome
Lupus,
September 1, 2005;
14(9):
691 - 696.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M Lockshin, F Tenedios, M Petri, G McCarty, R Forastiero, S Krilis, A Tincani, D Erkan, M A Khamashta, and Y Shoenfeld
Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report
Lupus,
July 1, 2003;
12(7):
518 - 523.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H Ilarraza, M F Marquez, A Alcocer, J L Banales, A H Nava, and P A Reyes
Anticardiolipin antibodies are not associated with rheumatic heart disease
Lupus,
December 1, 2001;
10(12):
873 - 875.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N Espinola-Zavaleta, M C Amigo, J Vargas-Barron, C Keirns, A R. Cardenas, M Vidal, and J Roldan
Two and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease
Lupus,
July 1, 2001;
10(7):
511 - 513.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M Turiel, S Muzzupappa, B Gottardi, C Crema, P Sarzi-Puttini, and E Rossi
Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography
Lupus,
July 1, 2000;
9(6):
406 - 412.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M Bijl, J Brouwer, and G G. Kallenberg
Grand Rounds from International Lupus Centres Cardiac abnormalities in SLE: pancarditis
Lupus,
May 1, 2000;
9(4):
236 - 240.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ziporen, I. Goldberg, M. Arad, M. Hojnik, J. Ordi-Ros, A. Afek, M. Blank, Y. Sandbank, M. Vilardell-Tarres, I. de Torres, et al.
Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves
Lupus,
June 1, 1996;
5(3):
196 - 205.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hojnik, J. George, L. Ziporen, and Y. Shoenfeld
Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome
Circulation,
April 15, 1996;
93(8):
1579 - 1587.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Morelli, C. Perrone, and G. Valesini
Tricuspid Valve Steno-Insufficiency in Systemic Lupus Erythematosus
Lupus,
August 1, 1995;
4(4):
318 - 320.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Krivda, J. S. Beard, J. A. Kovach, and W. D. James
Cutaneous Ulceration and a New Cardiac Murmur in a Young Woman
Arch Dermatol,
August 1, 1995;
131(8):
897 - 899.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Guzman and A. Thumala
Severe mitral valvular disease in systemic lupus erythematosus
Lupus,
February 1, 1995;
4(1):
79 - 79.
[PDF]
|
 |
|
|